Ping An Healthcare and Technology Future Growth
Future criteria checks 3/6
Ping An Healthcare and Technology is forecast to grow earnings and revenue by 53.6% and 7% per annum respectively. EPS is expected to grow by 51.6% per annum. Return on equity is forecast to be 0.9% in 3 years.
Key information
53.6%
Earnings growth rate
51.6%
EPS growth rate
| Consumer Retailing earnings growth | 28.8% |
| Revenue growth rate | 7.0% |
| Future return on equity | 0.9% |
| Analyst coverage | Good |
| Last updated | 20 Dec 2024 |
Recent future growth updates
Recent updates
Ping An Healthcare and Technology Company Limited (HKG:1833) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Nov 17
Ping An Healthcare and Technology Company Limited (HKG:1833) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
Sep 27Ping An Healthcare and Technology Company Limited (HKG:1833) Shares Could Be 49% Below Their Intrinsic Value Estimate
Sep 20Ping An Healthcare and Technology Company Limited's (HKG:1833) Share Price Not Quite Adding Up
Jul 17Revenues Not Telling The Story For Ping An Healthcare and Technology Company Limited (HKG:1833)
Apr 17Ping An Healthcare and Technology (HKG:1833) Is In A Strong Position To Grow Its Business
Mar 20Calculating The Fair Value Of Ping An Healthcare and Technology Company Limited (HKG:1833)
Jan 12Getting In Cheap On Ping An Healthcare and Technology Company Limited (HKG:1833) Is Unlikely
Dec 22We're Hopeful That Ping An Healthcare and Technology (HKG:1833) Will Use Its Cash Wisely
Sep 27A Look At The Intrinsic Value Of Ping An Healthcare and Technology Company Limited (HKG:1833)
Sep 10When Should You Buy Ping An Healthcare and Technology Company Limited (HKG:1833)?
Aug 02Here's Why We're Not Too Worried About Ping An Healthcare and Technology's (HKG:1833) Cash Burn Situation
Jun 26Ping An Healthcare and Technology Company Limited's (HKG:1833) Share Price Could Signal Some Risk
Jun 07Is There An Opportunity With Ping An Healthcare and Technology Company Limited's (HKG:1833) 46% Undervaluation?
Apr 04Should You Think About Buying Ping An Healthcare and Technology Company Limited (HKG:1833) Now?
Feb 16We Think Ping An Healthcare and Technology (HKG:1833) Can Afford To Drive Business Growth
Jan 23A Look At The Fair Value Of Ping An Healthcare and Technology Company Limited (HKG:1833)
Jan 02Companies Like Ping An Healthcare and Technology (HKG:1833) Are In A Position To Invest In Growth
Oct 11Estimating The Fair Value Of Ping An Healthcare and Technology Company Limited (HKG:1833)
Sep 14Companies Like Ping An Healthcare and Technology (HKG:1833) Are In A Position To Invest In Growth
Jun 22We're Hopeful That Ping An Healthcare and Technology (HKG:1833) Will Use Its Cash Wisely
Mar 01We're Not Very Worried About Ping An Healthcare and Technology's (HKG:1833) Cash Burn Rate
Nov 13Are Ping An Healthcare and Technology Company Limited (HKG:1833) Investors Paying Above The Intrinsic Value?
Oct 18Companies Like Ping An Healthcare and Technology (HKG:1833) Are In A Position To Invest In Growth
Aug 05Are Ping An Healthcare and Technology Company Limited (HKG:1833) Investors Paying Above The Intrinsic Value?
Jul 10We Think Ping An Healthcare and Technology (HKG:1833) Can Afford To Drive Business Growth
Apr 04If You Had Bought Ping An Healthcare and Technology (HKG:1833) Shares A Year Ago You'd Have Earned 47% Returns
Feb 28Are Institutions Heavily Invested In Ping An Healthcare and Technology Company Limited's (HKG:1833) Shares?
Jan 24
We Think Ping An Healthcare and Technology (HKG:1833) Can Easily Afford To Drive Business Growth
Dec 29Does This Valuation Of Ping An Healthcare and Technology Company Limited (HKG:1833) Imply Investors Are Overpaying?
Dec 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5,590 | 252 | 306 | 454 | 11 |
| 12/31/2025 | 5,445 | 168 | 189 | 352 | 13 |
| 12/31/2024 | 4,600 | 118 | 74 | 68 | 13 |
| 6/30/2024 | 4,545 | -21 | -387 | -351 | N/A |
| 3/31/2024 | 4,609 | -172 | -356 | -317 | N/A |
| 12/31/2023 | 4,674 | -323 | -326 | -283 | N/A |
| 9/30/2023 | 5,135 | -370 | -577 | -536 | N/A |
| 6/30/2023 | 5,596 | -418 | -829 | -789 | N/A |
| 3/31/2023 | 5,901 | -527 | -837 | -800 | N/A |
| 12/31/2022 | 6,205 | -636 | -845 | -811 | N/A |
| 9/30/2022 | 6,276 | -879 | -1,042 | -992 | N/A |
| 6/30/2022 | 6,347 | -1,121 | -1,239 | -1,174 | N/A |
| 3/31/2022 | 6,841 | -1,330 | -1,366 | -1,288 | N/A |
| 12/31/2021 | 7,334 | -1,538 | -1,492 | -1,403 | N/A |
| 9/30/2021 | 7,636 | -1,576 | -1,319 | -1,232 | N/A |
| 6/30/2021 | 7,938 | -1,614 | -1,145 | -1,060 | N/A |
| 3/31/2021 | 7,402 | -1,281 | -1,160 | -1,081 | N/A |
| 12/31/2020 | 6,866 | -948 | -1,175 | -1,102 | N/A |
| 9/30/2020 | 6,203 | -812 | -822 | -730 | N/A |
| 6/30/2020 | 5,539 | -675 | -469 | -358 | N/A |
| 3/31/2020 | 5,302 | -704 | -553 | -431 | N/A |
| 12/31/2019 | 5,065 | -734 | -637 | -504 | N/A |
| 9/30/2019 | 4,777 | -737 | -856 | -682 | N/A |
| 6/30/2019 | 4,488 | -740 | -1,075 | -859 | N/A |
| 3/31/2019 | 3,913 | -826 | -1,179 | -972 | N/A |
| 12/31/2018 | 3,338 | -912 | -1,283 | -1,085 | N/A |
| 9/30/2018 | 3,082 | -1,182 | -1,125 | -1,007 | N/A |
| 6/30/2018 | 2,542 | -990 | -866 | -827 | N/A |
| 3/31/2018 | 2,205 | -996 | N/A | -655 | N/A |
| 12/31/2017 | 1,868 | -1,002 | N/A | -484 | N/A |
| 9/30/2017 | 1,319 | -641 | N/A | -531 | N/A |
| 12/31/2016 | 601 | -758 | N/A | -263 | N/A |
| 12/31/2015 | 279 | -324 | N/A | -45 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1833 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: 1833 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 1833 is expected to become profitable in the next 3 years.
Revenue vs Market: 1833's revenue (7% per year) is forecast to grow slower than the Hong Kong market (7.8% per year).
High Growth Revenue: 1833's revenue (7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1833's Return on Equity is forecast to be low in 3 years time (0.9%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 09:22 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ping An Healthcare and Technology Company Limited is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaomeng Zhuang | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Hazim Bahari | CFRA Equity Research |